Genenta Science Posts Positive Glioblastoma Study Results, Initiates New Trials

Genenta Science announced follow-up observations in its glioblastoma multiforme study, with 38 patients enrolled and 25 receiving Temferon. Two patients have survived three years without disease progression, suggesting possible Temferon-mediated control. The survival rate at two years for unmethylated MGMT patients remained consistent at 29%, with median overall survival at 17 months. The company is also recruiting for a Phase 1 study of Temferon in genitourinary tumors and plans to demonstrate its safety and tolerability by year-end.